Bristol Myers Squibb’s CAR-T liso-cel wins long-delayed FDA nod


Bristol Myers Squibb
 gained FDA approval for its CAR-T drug liso-cel, which will be called Breyanzi. The drug will be available for patients with certain types of large B-cell lymphoma who haven’t responded to two other systemic treatments or who have relapsed after receiving those treatments. In a trial of more than 250 patients, 54% of patients who received the CAR-T therapy achieved complete remission.